Journal article · 2018 · Open access

RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model

Anna Mizutani, Yoko Yashiroda, Yukiko Muramatsu, Haruka Yoshida, Tsubasa Chikada, Takeshi Tsumura, Masayuki Okue, Fumiyuki Shirai, Takehiro Fukami, Minoru Yoshida, Hiroyuki Seimiya

Cancer Science, 109(12), 4003–4014 · Published 20 October 2018 · DOI 10.1111/cas.13805

Open PDFView at the publisherCite this paper

In brief

“RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model” is a 2018 journal article by Anna Mizutani and 10 co-authors, published in Cancer Science. OpenAlex counts 88 citations as of 21 November 2026, which puts it in the top 2% of works published in 2018 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Cancer Science.

Citations
88
Most cited in
2020 (19)
Field-weighted impact
2.82
References
33
Authors
11

Abstract

Aberrant activation of Wnt/β-catenin signaling causes tumorigenesis and promotes the proliferation of colorectal cancer cells. Porcupine inhibitors, which block secretion of Wnt ligands, may have only limited clinical impact for the treatment of colorectal cancer, because most colorectal cancer is caused by loss-of-function mutations of the tumor suppressor adenomatous polyposis coli (APC) downstream of Wnt ligands. Tankyrase poly(ADP-ribosyl)ates (PARylates) Axin, a negative regulator of β-catenin. This post-translational modification causes ubiquitin-dependent degradation of Axin, resulting in β-catenin accumulation. Tankyrase inhibitors downregulate β-catenin and suppress the growth of APC-mutated colorectal cancer cells. Herein, we report a novel tankyrase-specific inhibitor RK-287107, which inhibits tankyrase-1 and -2 four- and eight-fold more potently, respectively, than G007-LK, a tankyrase inhibitor that has been previously reported as effective in mouse xenograft models. RK-287107 causes Axin2 accumulation and downregulates β-catenin, T-cell factor/lymphoid enhancer factor reporter activity and the target gene expression in colorectal cancer cells harboring the shortly truncated APC mutations. Consistently, RK-287107 inhibits the growth of APC-mutated (β-catenin-dependent) colorectal cancer COLO-320DM and SW403 cells but not the APC-wild (β-catenin-independent) colorectal cancer RKO cells. Intraperitoneal or oral administration of RK-287107 suppresses COLO-320DM tumor growth in NOD-SCID mice. Rates of tumor growth inhibition showed good correlation with the behavior of pharmacodynamic biomarkers, such as Axin2 accumulation and MYC downregulation. These observations indicate that RK-287107 exerts a proof-of-concept antitumor effect, and thus may have potential for tankyrase-directed molecular cancer therapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., & Seimiya, H. (2018). RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Science, 109(12), 4003–4014. https://doi.org/10.1111/cas.13805

MLA 9

Mizutani, Anna, et al. “RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.” Cancer Science, vol. 109, no. 12, 2018, pp. 4003–4014. https://doi.org/10.1111/cas.13805.

Chicago

Mizutani, Anna, Yoko Yashiroda, Yukiko Muramatsu, Haruka Yoshida, Tsubasa Chikada, Takeshi Tsumura, Masayuki Okue, et al. 2018. “RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.” Cancer Science 109 (12): 4003–4014. https://doi.org/10.1111/cas.13805.

Harvard

Mizutani, A. et al. (2018) ‘RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model’, Cancer Science, 109(12), pp. 4003–4014. doi:10.1111/cas.13805.

IEEE

A. Mizutani et al., “RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model,” Cancer Science, vol. 109, no. 12, pp. 4003–4014, 2018, doi: 10.1111/cas.13805.

BibTeX

@article{mizutani2018potent,
  title     = {{RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model}},
  author    = {Mizutani, Anna and Yashiroda, Yoko and Muramatsu, Yukiko and Yoshida, Haruka and Chikada, Tsubasa and Tsumura, Takeshi and Okue, Masayuki and Shirai, Fumiyuki and Fukami, Takehiro and Yoshida, Minoru and Seimiya, Hiroyuki},
  journal   = {Cancer Science},
  year      = {2018},
  volume    = {109},
  number    = {12},
  pages     = {4003--4014},
  doi       = {10.1111/cas.13805},
  url       = {https://doi.org/10.1111/cas.13805}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201988
20201919
20211313
20221111
202377
20241414
202599
202666

Its field-weighted citation impact is 2.82: it has been cited 2.82 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • tankyrase inhibitors
  • tankyrase 1
  • TNKS2
  • colorectal cancer
  • Wnt/β-catenin signaling
  • Axin2
  • APC mutation
  • poly(ADP-ribosyl)ation

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Mizutani, A., Yashiroda, Y., Muramatsu, Y., Yoshida, H., Chikada, T., Tsumura, T., Okue, M., Shirai, F., Fukami, T., Yoshida, M., & Seimiya, H. (2018). RK ‐287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer Science, 109(12), 4003–4014. https://doi.org/10.1111/cas.13805

How many times has this paper been cited?

88 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Cancer Science: sign in and open the PDF from this page.

Who wrote this paper?

Anna Mizutani, Yoko Yashiroda, Yukiko Muramatsu, Haruka Yoshida, Tsubasa Chikada, Takeshi Tsumura, Masayuki Okue, Fumiyuki Shirai, Takehiro Fukami, Minoru Yoshida, Hiroyuki Seimiya.

What is the DOI of this paper?

10.1111/cas.13805, permanently at https://doi.org/10.1111/cas.13805. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.